Euronext Paris · Healthcare
Invest in Cegedim stock from India
Indian and foreign residents can buy Cegedim (ALCGM) shares directly through Paasa.
By Paasa · Updated
Cegedim at a glance
- Price
- €11.32-€0.02 (0.18%)
- Market cap
- €155.79M
- Day range
- €10.90 – €11.34
- P/E
- -10.58
- Dividend yield
- None
- Volume
- 2.82K
- 1 month
- +9.27%
- 6 months
- -3.25%
- YTD
- -16.46%
- 1 year
- +5.30%
- 5 years
- -57.04%
Cegedim statements, FY2020–FY2024
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | €654.5M | €616.0M | €555.2M | €524.7M | €496.9M |
| Gross profit | €624.9M | €255.6M | €528.6M | €498.0M | €471.4M |
| Operating income | €11.1M | €20.0M | €26.5M | €43.7M | €21.8M |
| Net income | −€14.7M | −€7.4M | €13.6M | €26.2M | €10.8M |
| Earnings per share | −€1.07 | −€0.54 | €1.00 | €1.90 | €0.78 |
| EBITDA | €101.6M | €95.3M | €95.0M | €103.6M | €60.7M |
| Total assets | €986.9M | €924.1M | €889.9M | €797.6M | €905.4M |
| Total debt | €325.8M | €285.1M | €284.6M | €275.5M | €266.5M |
| Cash and short-term investments | €49.6M | €46.6M | €55.6M | €24.2M | €24.7M |
| Shareholders' equity | €264.3M | €276.2M | €285.2M | €232.1M | €207.7M |
| Operating cash flow | €101.8M | €97.9M | €86.5M | €96.0M | €110.4M |
| Free cash flow | €11.9M | €22.4M | €10.3M | €45.2M | €35.9M |
| Capital expenditure | −€89.9M | −€75.5M | −€76.1M | −€50.7M | −€74.5M |
Fiscal years as reported, the latest ending 31 Dec 2024. Figures in EUR; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Biocorp Production | ALCOR.PA | €35.10 | €154.53M |
| Visiomed | ALVMG.PA | €0.17 | €52.99M |
| Mauna Kea Technologies | MKEA.PA | €0.62 | €30.17M |
| Nicox | COX.PA | €0.58 | €29.04M |
| Fermentalg | FALG.PA | €0.56 | €23.95M |
| Pherecydes Pharma | ALPHE.PA | €2.00 | €15.83M |
| Carmat | ALCAR.PA | €0.10 | €6.36M |
| Health | MLAHC.PA | €0.60 | €5.41M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Cegedim from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to EUR when you buy.
Step 3
Search ALCGM and buy
Find Cegedim by name or by its ticker, ALCGM, and place your order.
Why invest in Cegedim from India
What Cegedim does
Cegedim SA operates as a technology and services firm dedicated to digital data flow management within the healthcare ecosystem and business-to-business (B2B) sectors. Its operations extend across France, other European countries, and internationally. Cegedim operates in the Medical - Healthcare Information Services industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Cegedim stock from India?
Yes. Indian residents and NRIs can buy Cegedim (ALCGM) shares directly through Paasa. Cegedim is listed on Euronext Paris, in the Medical - Healthcare Information Services industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Cegedim shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the EUR/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.